AstraZeneca (AZN) said Monday that its shares will begin trading on the New York Stock Exchange for the first time, effective at the opening bell.

With the switch to the exchange from Nasdaq, AstraZeneca shares will now trade on the NYSE, the London Stock Exchange and Nasdaq Stockholm "under a harmonised listing structure," the drugmaker said.

Separately, the company said Imfinzi as perioperative regimen therapy has been recommended for approval by the European Union's Committee for Medicinal Products for Human Use for the treatment of patients with early gastric and gastroesophageal cancers.

The recommendation is based on results from a phase 3 trial which showed a 29% reduction in the risk of disease progression, recurrence, or death and a 22% reduction in the risk of death for the Imfinzi regimen compared with chemotherapy alone, the company said.

The therapy includes Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, and finally Imfinzi as a monotherapy, the company said.

The safety profile for combination was consistent with the known profiles of each medicine, the company said, adding Imfinzi is already approved in the US and elsewhere for the same indication.